Daiichi Sankyo-AstraZeneca Gets BLA Approved for Lung Cancer Therapy in the U.S.
DATO-DXD jointly developed by Daiichi Sankyo/AstraZeneca (AZN.US)
On February 19, Daiichi Sankyo/AstraZeneca (AZN.US) jointly announced that its dato-DXD biological product license application (BLA) was accepted by the FDA for use in adult patients with locally advanced or metastatic non-squamous NSCLC who have previously received systemic treatment. The PDUFA date is December 20, 2024.
Pharma Giants Turn to China in Search of Targeted Cancer Drugs
Daiichi Sankyo Reports 9M Results
Merck Posts Q4 Beat as Keytruda Outperforms
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On March 28th, 2024 With 0.264 USD Dividend Per Share
February 1st - $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ is trading ex-dividend on March 28th, 2024. Shareholders of record on March 31st, 2024 will receive 0.264 USD dividend per share on June 2